Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

The ‘Iron man suit’ for QA Managers: Quality management software taps power of ChatGPT

By Brian Buntz | April 4, 2023

Dot ComplianceGone are the days when Microsoft’s animated paperclip, Clippy, popped up on your screen with helpful — and sometimes annoying — tips and tricks for your Word document. Now, the Israeli eQMS compliance provider Dot Compliance has launched what it hails as an industry-first electronic Quality Management System (eQMS) for life sciences with a prominent generative AI-enhanced digital assistant that could take intelligent assistance to new heights. “It’s not just ChatGPT. It’s many other algorithms that are evolving,” said Doron Sitbon, founder and CEO of the company.

Transforming quality assurance with AI-driven quality management software

Rather than Clippy, Sitbon uses another metaphor to illustrate the company’s ChatGPT-enhanced “Dottie” capabilities for its QMS Xpress quality management software. “I think of it as an Iron Man suit for a [quality assurance] manager,” Sitbon quipped. The Dottie digital assistant pops up offering context-based advice on how to deal with specific quality deviations.

Chat GPT Screenshot

[Image courtesy of Dot Compliance]

Indeed, the capabilities of a quality assurance (QA) professional today are not incrementally improved with generative AI. The technology could offer significantly new QA capabilities given the combination of AI trained on QA professionals’ input.

Sitbon emphasized that the goal is not to replace the judgment of the QA manager. Instead, the AI-enhanced eQMS allows them to see more, move faster, and parse larger sets of information. “The future is now,” he added.

Dot Compliance believes their quality management software offers QA managers in the life sciences an unparalleled level of support, efficiency, and expertise. “AI would assist the QA manager of the future in analyzing distinct data points into a cohesive picture,” Sitbon said.

For Dot Compliance, the AI itself is not the point. Conversely, the main focus is the combination of generative AI with domain expertise, Sitbon said. Those capabilities could make it possible for non-technical individuals to influence quality assurance workflows more. “Our goal as a vendor is to remove the obstacles, making [eQMS capabilities] available to people that are not technical,” Sitbon said. “You have to take the domain knowledge and technological expertise and create a blend that makes sense to users.”

Overcoming regulatory hurdles and boosting efficiency in life sciences

By using the ChatGPT API with proprietary algorithms, Dot Compliance’s eQMS delivers real-time, intelligent assistance that not only streamlines workflows but also enhances the compliance of life science organizations. The system’s AI-driven capabilities help QA managers to make informed decisions and enforce good quality management practices, thereby reducing the risk of costly regulatory violations, according to Sitbon.

Doron Sitbon

Doron Sitbon

In recent years, regulatory bodies such as the FDA and EMA have levied millions of dollars in fines on life science companies for violations of quality and safety standards. The use of AI to make informed decisions and enforce good quality management practices can significantly reduce these costs, making a notable impact on the industry’s bottom line, Sitbon explained.

The AI-driven quality management software aims to optimize quality processes, automate tasks, and help professionals in quality assurance focus on mission-critical activities. By seamlessly integrating AI-driven quality management into existing processes, manufacturers can benefit from a system that constantly learns and evolves to offer increasingly accurate insights and predictions.

As the life sciences industry continues to evolve, the need for intelligent assistance in managing complex regulatory demands will only increase, Sitbon predicted. The AI-based eQMS, powered by ChatGPT and other algorithms, could represent a significant step forward in transforming the quality and compliance space. “It’s pretty exciting; it’s almost like science fiction,” Sitbon said.


Filed Under: Data science
Tagged With: AI-based eQMS, AI-driven quality management, ChatGPT, Dot Compliance, EMA, eQMS, FDA, generative AI, life sciences, QA managers, quality assurance
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Capgemini’s life-sciences lead says ROI and data security, not algorithms, will decide pharma’s AI future
Portrait of happy smiling mature middle aged professional business woman investor manager executive or lawyer attorney looking at camera at workplace working on laptop computer in office.
As FDA pushes agency-wide generative AI, pharma experience show similar tools can cut clinical study-report drafting time by 30% or more
FDA’s genAI push could save CDER hundreds of thousands of review hours annually
Elsevier plugs 500,000 ClinicalTrials.gov records into Embase
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE